Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Apr 18;282(6272):1259–1262. doi: 10.1136/bmj.282.6272.1259

In-vitro venous prostacyclin production, plasma 6-keto-prostaglandin F1 alpha concentrations, and diabetic retinopathy.

T M Davis, E Bown, D R Finch, M D Mitchell, R C Turner
PMCID: PMC1505380  PMID: 6784805

Abstract

Previous studies have shown that vessels from diabetics produce less prostacyclin in vitro than those from normal controls. To determine whether this decreased production is related to complications elective biopsy of a superficial forearm vein was performed on 12 insulin-dependent male diabetics, six with nil or minimal and six with proliferative retinopathy, and seven male controls. Vein segments from the diabetics and controls produced similar amounts of prostacyclin in vitro (medians 0.11 and 0.19 ng/mg tissue respectively), but the segments from the diabetics with nil or minimal retinopathy produced less than those from the diabetics with proliferative retinopathy (medians 0.09 and 0.18 ng/mg respectively). Preoperative plasma immunoreactive concentrations of 6-keto-prostaglandin F1 alpha were not significantly different between the controls and the diabetics (medians 101 and 116 pg/ml respectively). In a separate study, however, 11 diabetics with duration of disease of over 10 years and nil or minimal retinopathy had significantly lower concentrations than a matched group of 16 with background or proliferative retinopathy (medians 79 and 121 pg/ml respectively). These results do not support an association between reduced prostacyclin production and diabetic retinopathy.

Full text

PDF
1259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davis T. M., Mitchell M. D., Dornan T. L., Turner R. G. Plasma 6-keto-PGF1 alpha concentrations and diabetic retinopathy. Lancet. 1980 Feb 16;1(8164):373–373. doi: 10.1016/s0140-6736(80)90924-1. [DOI] [PubMed] [Google Scholar]
  2. Davis T. M., Mitchell M. D., Turner R. C. Prostacyclin and thromboxane metabolites in diabetes. Lancet. 1979 Oct 13;2(8146):789–790. doi: 10.1016/s0140-6736(79)92131-7. [DOI] [PubMed] [Google Scholar]
  3. De Bono D. En face organ culture of vascular endothelium. Br J Exp Pathol. 1975 Feb;56(1):8–13. [PMC free article] [PubMed] [Google Scholar]
  4. Dollery C. T., Friedman L. A., Hensby C. N., Kohner E., Lewis P. J., Porta M., Webster J. Circulating prostacyclin may be reduced in diabetes. Lancet. 1979 Dec 22;2(8156-8157):1365–1365. doi: 10.1016/s0140-6736(79)92844-7. [DOI] [PubMed] [Google Scholar]
  5. Garcia M. J., McNamara P. M., Gordon T., Kannel W. B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974 Feb;23(2):105–111. doi: 10.2337/diab.23.2.105. [DOI] [PubMed] [Google Scholar]
  6. Harrison H. E., Reece A. H., Johnson M. Decreased vascular prostacyclin in experimental diabetes. Life Sci. 1978 Jul 24;23(4):351–355. doi: 10.1016/0024-3205(78)90020-6. [DOI] [PubMed] [Google Scholar]
  7. Harrison H. E., Reece A. H., Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia. 1980 Jan;18(1):65–68. doi: 10.1007/BF01228305. [DOI] [PubMed] [Google Scholar]
  8. Jarrett R. J., Keen H. Hyperglycaemia and diabetes mellitus. Lancet. 1976 Nov 6;2(7993):1009–1012. doi: 10.1016/s0140-6736(76)90844-8. [DOI] [PubMed] [Google Scholar]
  9. Johnson M., Harrison H. E., Raftery A. T., Elder J. B. Vascular prostacyclin may be reduced in diabetes in man. Lancet. 1979 Feb 10;1(8111):325–326. doi: 10.1016/s0140-6736(79)90737-2. [DOI] [PubMed] [Google Scholar]
  10. Jørgensen K. A., Stoffersen E., Dyerberg J. Stability of prostacyclin in plasma. Lancet. 1979 Jun 23;1(8130):1352–1352. doi: 10.1016/s0140-6736(79)91987-1. [DOI] [PubMed] [Google Scholar]
  11. Kynoch P. A., Lehmann H. Rapid estimation (2 1/2 hours) of glycosylated haemoglobin for routine purposes. Lancet. 1977 Jul 2;2(8027):16–16. doi: 10.1016/s0140-6736(77)90007-1. [DOI] [PubMed] [Google Scholar]
  12. Mitchell M. D. A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations. Prostaglandins Med. 1978 Jul;1(1):13–21. doi: 10.1016/0161-4630(78)90072-1. [DOI] [PubMed] [Google Scholar]
  13. Moncada S., Higgs E. A., Vane J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18–20. doi: 10.1016/s0140-6736(77)91655-5. [DOI] [PubMed] [Google Scholar]
  14. Moncada S., Vane J. R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979 May 17;300(20):1142–1147. doi: 10.1056/NEJM197905173002006. [DOI] [PubMed] [Google Scholar]
  15. Pace-Asciak C. R., Carrara M. C. Age-dependent increase in the formation of prostaglandin I2 by intact and homogenised aortae from the developing spontaneously hypertensive rat. Biochim Biophys Acta. 1979 Jul 27;574(1):177–181. doi: 10.1016/0005-2760(79)90097-3. [DOI] [PubMed] [Google Scholar]
  16. Pirart J. Rigueur du traitement du diabète et complications rétiniennes. Journ Annu Diabetol Hotel Dieu. 1977:282–296. [PubMed] [Google Scholar]
  17. Rösen P., Schrör K. Increased prostacyclin release from perfused hearts of acutely diabetic rats. Diabetologia. 1980 May;18(5):391–394. doi: 10.1007/BF00276820. [DOI] [PubMed] [Google Scholar]
  18. Silberbauer K., Schernthaner G., Sinzinger H., Piza-Katzer H., Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. N Engl J Med. 1979 Feb 15;300(7):366–367. [PubMed] [Google Scholar]
  19. Steer M. L., MacIntyre D. E., Levine L., Salzman E. W. Is prostacyclin a physiologically important circulating anti-platelet agent? Nature. 1980 Jan 10;283(5743):194–195. doi: 10.1038/283194a0. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES